Business Wire

CA-ARRCUS

18.7.2024 15:01:36 CEST | Business Wire | Press release

Share
Arrcus Continues Networking Innovation Fueled by New $30M Investment

Arrcus, the hyperscale networking software company and a leader in core, edge, and multi-cloud routing and switching infrastructure, today announced a significant new investment of $30 million from Prosperity7 Ventures, NVIDIA, Lightspeed, Hitachi Ventures, Liberty Global, Clear Ventures, and General Catalyst. Growing investor interest in the company comes alongside Arrcus’ success with leading Fortune 500 and Global 2000 customers and will enable the company to expand platform support, accelerate growth, and continue delivering cost-effective and transformational networking solutions to customers worldwide.

As the unprecedented adoption of AI continues, there is a growing need for distributed networking to improve the efficiency of compute infrastructure spanning datacenter, 5G, edge and hybrid/multi-cloud environments across enterprise, cloud, and network operators. Arrcus’ uniquely differentiated routing and switching platform, Arrcus Connected Edge (ACE), features a distributed microservices architecture that is flexible, high-performance, scalable, fully programmable, modular, and hybrid cloud-ready. It is deployable on various form factors, including data processing units (DPUs), merchant silicon, and compute, and enables a wide range of use cases including low-latency data center networking, modern edge deployments, telco access and transport, and hybrid multi-cloud connectivity.

Arrcus’ ACE networking platform, leveraging the NVIDIA BlueField DPU, enables customers to efficiently offload, accelerate, and isolate compute-intensive networking applications like security and traffic engineering. With the advent of GenAI applications, this gives customers the ability to have high performance secure connectivity within the data center, while delivering higher utilization and power efficiency for compute-intensive workloads.

"We are thrilled to welcome NVIDIA as our latest investor and look forward to building on our collaboration. Arrcus’ leading networking software coupled with NVIDIA's AI infrastructure will help deliver maximum efficiency to customers from data centers as well as their edge and cloud computing environments," said Shekar Ayyar, Chairman and CEO of Arrcus. "We also extend our gratitude to Prosperity7, Lightspeed, Hitachi Ventures, Liberty Global, Clear Ventures, and General Catalyst for their continued support and confidence in our vision."

This collaboration between NVIDIA and Arrcus can help extend AI data center architectures to distributed configurations supported by modular designs such as the NVIDIA MGX platform.

“Modern networks are evolving to address customer needs in the era of AI,” said Kevin Deierling, senior vice president of networking at NVIDIA. “We’re collaborating with Arrcus to provide high-performance, secure and cost-efficient data center networking for a variety of accelerated computing applications.”

Arrcus is garnering significant attention for its innovative networking software solutions that enable businesses to achieve substantial cost savings while improving scalability, performance, and reliability in core, edge, and multi-cloud infrastructures. Arrcus networking is ideally suited for the telecom, financial services, and industrial verticals, amongst others.

“AI is driving the need for more flexible networking to maximize the impact of high-performance compute cycles,” said Jason Hardy, CTO for AI, Hitachi Vantara. “We are pleased to see Arrcus software working across leading industry hardware platforms for distributed datacenter networking.”

“We are excited to see the new investment in Arrcus. Arrcus networking has the potential for high performance at lower cost for datacenter and carrier networks, as well as meeting the demands of infrastructure for AI and 5G,” said Adrian Drury, MD Platform Technology Liberty Global.

“Arrcus is driving an exciting disruption in networking for datacenters and AI. After leading their D round, we are now excited to join NVIDIA and other investors in continuing to support their growth and platform adoption among leading customers,” said Abhishek Shukla, Managing Director, Prosperity7 Ventures.

"Arrcus continues to push the boundaries of networking innovation with their ACE platform. Their unique approach to leveraging distributed microservices architecture and integration with leading hardware platforms enables a wide range of networking use cases from the edge to datacenters to multi-clouds, setting them apart in the industry,” said Alan Weckel, Co-Founder and Technology Analyst at 650 Group. “This new investment further validates Arrcus' vision and capability to deliver high-performance, scalable, and cost-efficient networking solutions that meet the evolving demands of AI-driven environments."

For more information please click here.

Additional Resources

About Arrcus

Arrcus is a leading provider of networking software solutions that empower businesses to achieve unparalleled scalability, performance, and reliability in their infrastructure. Arrcus is disrupting the industry with disaggregated solutions that deliver innovative, agile, and cost-effective networking, allowing enterprises to break free from traditional, monolithic systems and embrace a more flexible, efficient, and scalable approach to modern networking. The Arrcus team consists of world-class technologists who have an unparalleled record in shipping industry-leading networking products, complemented by industry thought leaders, operating executives, strategic partners, and top-tier VCs. The company is headquartered in San Jose, Calif. For more information, go to www.arrcus.com or follow Arrcus on LinkedIn and Twitter/X.

About Prosperity7

Prosperity7 Ventures (P7) is the diversified growth fund of Aramco Ventures, a subsidiary of Aramco, the world's leading integrated energy and chemicals company. The fund's name derives from "Prosperity Well', the 7th oil well drilled in Saudi Arabia and the first to strike oil. Taking forward this pioneering history, P7 invests globally with a long-term view in breakthrough technologies and transformational business models that will bring prosperity and positive impact on a vast scale.

For more information, please visit https://www.prosperity7vc.com/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240718299242/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN® APN6.8.2026 06:30:00 CEST | Press release

NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o

FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release

Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release

Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted

Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release

Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye